| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, Notch1 | 23 | 2022 | 61 | 3.850 |
Why?
|
| Apoptosis | 37 | 2016 | 1033 | 2.690 |
Why?
|
| Signal Transduction | 44 | 2020 | 2903 | 2.640 |
Why?
|
| Receptors, Notch | 21 | 2020 | 101 | 2.610 |
Why?
|
| T-Lymphocytes | 31 | 2020 | 986 | 2.190 |
Why?
|
| Cell Differentiation | 19 | 2023 | 1304 | 1.570 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2023 | 623 | 1.400 |
Why?
|
| Lymphocyte Activation | 15 | 2020 | 743 | 1.290 |
Why?
|
| Thymus Gland | 14 | 2004 | 229 | 1.230 |
Why?
|
| Amyloid Precursor Protein Secretases | 13 | 2023 | 69 | 1.000 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2023 | 207 | 0.970 |
Why?
|
| Animals | 104 | 2023 | 19650 | 0.970 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2012 | 281 | 0.940 |
Why?
|
| Immunization, Secondary | 1 | 2024 | 40 | 0.900 |
Why?
|
| Mice | 68 | 2023 | 10294 | 0.880 |
Why?
|
| Saliva | 1 | 2024 | 100 | 0.870 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 95 | 0.850 |
Why?
|
| Jagged-1 Protein | 2 | 2020 | 8 | 0.840 |
Why?
|
| Receptors, Cell Surface | 10 | 2005 | 428 | 0.830 |
Why?
|
| DNA-Binding Proteins | 15 | 2015 | 1151 | 0.810 |
Why?
|
| Calcium-Binding Proteins | 3 | 2020 | 87 | 0.800 |
Why?
|
| Gene Expression Regulation | 17 | 2020 | 1552 | 0.800 |
Why?
|
| Transcription Factors | 18 | 2018 | 1471 | 0.800 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 297 | 0.780 |
Why?
|
| Graft vs Host Disease | 5 | 2023 | 105 | 0.780 |
Why?
|
| CD28 Antigens | 3 | 2020 | 60 | 0.770 |
Why?
|
| Th17 Cells | 4 | 2023 | 57 | 0.700 |
Why?
|
| Membrane Proteins | 12 | 2015 | 850 | 0.680 |
Why?
|
| Neoplasms | 11 | 2022 | 1231 | 0.670 |
Why?
|
| Macrophages | 10 | 2019 | 1015 | 0.660 |
Why?
|
| Genes, Immunoglobulin | 8 | 2002 | 32 | 0.640 |
Why?
|
| Antineoplastic Agents | 7 | 2020 | 628 | 0.600 |
Why?
|
| Antibodies | 5 | 2021 | 179 | 0.590 |
Why?
|
| Mice, Inbred C57BL | 20 | 2020 | 3231 | 0.590 |
Why?
|
| Cysteine Endopeptidases | 4 | 2003 | 92 | 0.590 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 4 | 2018 | 7 | 0.570 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 411 | 0.560 |
Why?
|
| Receptors, Steroid | 9 | 2009 | 25 | 0.530 |
Why?
|
| NF-kappa B | 8 | 2018 | 460 | 0.520 |
Why?
|
| Cell Proliferation | 3 | 2018 | 941 | 0.510 |
Why?
|
| Interferon-gamma | 7 | 2020 | 551 | 0.490 |
Why?
|
| Forkhead Transcription Factors | 3 | 2020 | 125 | 0.490 |
Why?
|
| Multienzyme Complexes | 3 | 2003 | 76 | 0.480 |
Why?
|
| Mice, Transgenic | 12 | 2020 | 1206 | 0.480 |
Why?
|
| Immunoconjugates | 3 | 2022 | 85 | 0.480 |
Why?
|
| Gene Expression | 6 | 2019 | 809 | 0.470 |
Why?
|
| Mitochondria | 4 | 2014 | 343 | 0.460 |
Why?
|
| Protease Inhibitors | 4 | 2013 | 104 | 0.450 |
Why?
|
| Models, Immunological | 2 | 2012 | 85 | 0.430 |
Why?
|
| Protein Kinase C-theta | 4 | 2023 | 16 | 0.430 |
Why?
|
| Humans | 72 | 2024 | 59389 | 0.430 |
Why?
|
| Cells, Cultured | 20 | 2020 | 2092 | 0.430 |
Why?
|
| Th1 Cells | 4 | 2018 | 177 | 0.420 |
Why?
|
| Mice, Inbred BALB C | 16 | 2015 | 868 | 0.410 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 5 | 2020 | 57 | 0.400 |
Why?
|
| Cell Death | 9 | 2003 | 271 | 0.400 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2015 | 289 | 0.380 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 98 | 0.370 |
Why?
|
| Amyloid beta-Protein Precursor | 3 | 2020 | 77 | 0.370 |
Why?
|
| Immunoglobulin lambda-Chains | 5 | 2002 | 10 | 0.360 |
Why?
|
| Hyperbaric Oxygenation | 3 | 2005 | 16 | 0.360 |
Why?
|
| Cell-Penetrating Peptides | 3 | 2020 | 27 | 0.340 |
Why?
|
| Gene Conversion | 5 | 1997 | 6 | 0.340 |
Why?
|
| Cattle | 6 | 2002 | 304 | 0.340 |
Why?
|
| Oxygen | 5 | 2005 | 313 | 0.330 |
Why?
|
| Endopeptidases | 4 | 2005 | 68 | 0.330 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 10 | 0.330 |
Why?
|
| Enterotoxins | 4 | 2016 | 20 | 0.320 |
Why?
|
| HEK293 Cells | 5 | 2020 | 587 | 0.320 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2009 | 147 | 0.320 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 70 | 0.320 |
Why?
|
| Breast Neoplasms | 6 | 2017 | 1118 | 0.320 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2009 | 74 | 0.320 |
Why?
|
| MAP Kinase Signaling System | 2 | 2014 | 203 | 0.320 |
Why?
|
| Cell Line | 15 | 2014 | 1983 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2008 | 10 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2008 | 16 | 0.310 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2019 | 37 | 0.310 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2022 | 651 | 0.310 |
Why?
|
| Cyclins | 1 | 2008 | 40 | 0.310 |
Why?
|
| Macrophage Activation | 2 | 2014 | 118 | 0.310 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 46 | 0.300 |
Why?
|
| Cell Nucleus | 5 | 2012 | 608 | 0.300 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 53 | 0.300 |
Why?
|
| Antibodies, Bacterial | 3 | 2016 | 187 | 0.290 |
Why?
|
| Cytokines | 9 | 2020 | 915 | 0.290 |
Why?
|
| Base Sequence | 13 | 2008 | 1302 | 0.290 |
Why?
|
| Antibodies, Neutralizing | 2 | 2024 | 178 | 0.290 |
Why?
|
| Promoter Regions, Genetic | 8 | 2020 | 650 | 0.290 |
Why?
|
| Receptor, ErbB-2 | 3 | 2021 | 49 | 0.280 |
Why?
|
| Immune System | 3 | 1999 | 129 | 0.280 |
Why?
|
| Toll-Like Receptors | 2 | 2014 | 426 | 0.270 |
Why?
|
| Immunoglobulin Heavy Chains | 6 | 2002 | 42 | 0.270 |
Why?
|
| Immunotherapy | 5 | 2022 | 228 | 0.270 |
Why?
|
| Immunoglobulin Variable Region | 5 | 2001 | 31 | 0.270 |
Why?
|
| Dexamethasone | 4 | 2003 | 201 | 0.260 |
Why?
|
| Immune Tolerance | 4 | 2020 | 172 | 0.260 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 8 | 2009 | 13 | 0.250 |
Why?
|
| Intracellular Fluid | 2 | 2020 | 32 | 0.250 |
Why?
|
| I-kappa B Proteins | 1 | 2005 | 39 | 0.250 |
Why?
|
| Acetylcysteine | 3 | 2003 | 27 | 0.250 |
Why?
|
| Mammary Glands, Human | 1 | 2005 | 53 | 0.240 |
Why?
|
| Transcription, Genetic | 7 | 2018 | 841 | 0.240 |
Why?
|
| Lymphocytes | 2 | 2007 | 190 | 0.240 |
Why?
|
| Presenilin-1 | 3 | 2019 | 57 | 0.240 |
Why?
|
| Transfection | 5 | 2015 | 675 | 0.230 |
Why?
|
| CD3 Complex | 2 | 2020 | 63 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2016 | 217 | 0.230 |
Why?
|
| Antibody Formation | 2 | 2024 | 108 | 0.230 |
Why?
|
| Female | 25 | 2024 | 30724 | 0.230 |
Why?
|
| Antibody Diversity | 4 | 2001 | 7 | 0.220 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 1368 | 0.220 |
Why?
|
| Lipopolysaccharides | 6 | 2018 | 627 | 0.220 |
Why?
|
| Drug Delivery Systems | 3 | 2020 | 312 | 0.220 |
Why?
|
| Sulindac | 1 | 2023 | 5 | 0.220 |
Why?
|
| HLA-A2 Antigen | 1 | 2023 | 64 | 0.210 |
Why?
|
| Interleukin-6 | 2 | 2023 | 309 | 0.210 |
Why?
|
| Multiple Sclerosis | 2 | 2020 | 207 | 0.210 |
Why?
|
| Phosphorylation | 5 | 2016 | 883 | 0.210 |
Why?
|
| Cell Plasticity | 1 | 2023 | 18 | 0.210 |
Why?
|
| Staphylococcus aureus | 3 | 2016 | 169 | 0.210 |
Why?
|
| Spleen | 10 | 2010 | 479 | 0.210 |
Why?
|
| Presenilin-2 | 2 | 2020 | 20 | 0.210 |
Why?
|
| Lymphoma | 2 | 2022 | 99 | 0.200 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 323 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2020 | 616 | 0.200 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 59 | 0.200 |
Why?
|
| Adoptive Transfer | 2 | 2020 | 147 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2023 | 238 | 0.190 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2003 | 244 | 0.190 |
Why?
|
| Flow Cytometry | 7 | 2014 | 645 | 0.190 |
Why?
|
| Fullerenes | 1 | 2021 | 2 | 0.190 |
Why?
|
| Hybridomas | 2 | 1999 | 64 | 0.190 |
Why?
|
| B-Lymphocytes | 9 | 2010 | 552 | 0.180 |
Why?
|
| Immunomodulation | 2 | 2018 | 28 | 0.180 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2018 | 7 | 0.180 |
Why?
|
| Disease Models, Animal | 7 | 2023 | 2053 | 0.180 |
Why?
|
| Nanoparticles | 3 | 2022 | 493 | 0.180 |
Why?
|
| Ligands | 2 | 2020 | 411 | 0.170 |
Why?
|
| Protein D-Aspartate-L-Isoaspartate Methyltransferase | 1 | 2020 | 4 | 0.170 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein L | 1 | 2020 | 4 | 0.170 |
Why?
|
| Maytansine | 1 | 2020 | 3 | 0.170 |
Why?
|
| Caspases | 4 | 2003 | 166 | 0.170 |
Why?
|
| Alzheimer Disease | 5 | 2019 | 679 | 0.170 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2018 | 276 | 0.170 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 54 | 0.170 |
Why?
|
| Protein Biosynthesis | 1 | 2002 | 297 | 0.170 |
Why?
|
| Cell Cycle | 3 | 1999 | 382 | 0.160 |
Why?
|
| Molecular Sequence Data | 11 | 2007 | 1951 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 157 | 0.160 |
Why?
|
| Protein Kinase C | 2 | 2016 | 98 | 0.160 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 7 | 2002 | 142 | 0.160 |
Why?
|
| Fluorine | 1 | 2019 | 9 | 0.160 |
Why?
|
| Caenorhabditis elegans | 2 | 1996 | 623 | 0.160 |
Why?
|
| I-kappa B Kinase | 2 | 2009 | 48 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2008 | 318 | 0.160 |
Why?
|
| Myeloid Cells | 2 | 2018 | 89 | 0.160 |
Why?
|
| Eukaryotic Cells | 1 | 1999 | 57 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2015 | 474 | 0.150 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2019 | 87 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1998 | 50 | 0.150 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 55 | 0.150 |
Why?
|
| Helminth Proteins | 2 | 1996 | 39 | 0.150 |
Why?
|
| Down-Regulation | 3 | 2011 | 306 | 0.150 |
Why?
|
| Muridae | 2 | 1988 | 8 | 0.140 |
Why?
|
| Blotting, Western | 4 | 2014 | 583 | 0.140 |
Why?
|
| Mice, Knockout | 5 | 2015 | 1997 | 0.140 |
Why?
|
| T-Box Domain Proteins | 2 | 2009 | 37 | 0.140 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2019 | 139 | 0.140 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 75 | 0.140 |
Why?
|
| Interleukin-17 | 3 | 2015 | 88 | 0.140 |
Why?
|
| Antigens, CD | 3 | 2012 | 343 | 0.140 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 679 | 0.140 |
Why?
|
| Amino Acid Sequence | 4 | 2014 | 1553 | 0.140 |
Why?
|
| Prion Proteins | 1 | 2016 | 4 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 3 | 2020 | 196 | 0.130 |
Why?
|
| Immunization, Passive | 1 | 2016 | 99 | 0.130 |
Why?
|
| Vertebrates | 1 | 1996 | 41 | 0.130 |
Why?
|
| Protein Binding | 4 | 2020 | 1555 | 0.130 |
Why?
|
| Isoenzymes | 1 | 2016 | 136 | 0.130 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2015 | 256 | 0.130 |
Why?
|
| Pneumonia | 2 | 2016 | 281 | 0.130 |
Why?
|
| Hybrid Cells | 7 | 1999 | 16 | 0.130 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 365 | 0.130 |
Why?
|
| Metabolism | 1 | 2015 | 12 | 0.130 |
Why?
|
| Genes, Regulator | 1 | 1996 | 28 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 328 | 0.130 |
Why?
|
| Nylons | 1 | 2015 | 7 | 0.130 |
Why?
|
| Polyethyleneimine | 1 | 2015 | 7 | 0.130 |
Why?
|
| Dendritic Cells | 4 | 2023 | 515 | 0.120 |
Why?
|
| Muscles | 2 | 2015 | 173 | 0.120 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2015 | 11 | 0.120 |
Why?
|
| Granzymes | 2 | 2020 | 18 | 0.120 |
Why?
|
| Up-Regulation | 4 | 2016 | 365 | 0.120 |
Why?
|
| Amyloid beta-Peptides | 2 | 2020 | 286 | 0.120 |
Why?
|
| Fructose | 1 | 2015 | 36 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 446 | 0.120 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 122 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 106 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 347 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 1998 | 339 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2003 | 122 | 0.120 |
Why?
|
| Blastocyst | 1 | 2015 | 70 | 0.120 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1995 | 24 | 0.120 |
Why?
|
| Lymphoma, T-Cell | 2 | 2008 | 22 | 0.120 |
Why?
|
| Aspartic Acid Endopeptidases | 2 | 2005 | 30 | 0.110 |
Why?
|
| Metalloendopeptidases | 1 | 1994 | 22 | 0.110 |
Why?
|
| RGS Proteins | 1 | 2014 | 2 | 0.110 |
Why?
|
| Young Adult | 1 | 2024 | 4272 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 165 | 0.110 |
Why?
|
| Protein Subunits | 2 | 2013 | 165 | 0.110 |
Why?
|
| Protein Transport | 3 | 2015 | 399 | 0.110 |
Why?
|
| Genes, Reporter | 1 | 1995 | 241 | 0.110 |
Why?
|
| Receptor, Notch2 | 3 | 2008 | 8 | 0.110 |
Why?
|
| Biological Evolution | 3 | 1994 | 114 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2015 | 254 | 0.110 |
Why?
|
| Molecular Chaperones | 1 | 2014 | 99 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 100 | 0.110 |
Why?
|
| Homeostasis | 1 | 1996 | 346 | 0.110 |
Why?
|
| Genetic Variation | 1 | 1995 | 357 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 331 | 0.110 |
Why?
|
| Cell Survival | 4 | 2016 | 559 | 0.100 |
Why?
|
| Cell Division | 3 | 2008 | 443 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 188 | 0.100 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2010 | 62 | 0.100 |
Why?
|
| Reactive Oxygen Species | 4 | 2014 | 205 | 0.100 |
Why?
|
| Sheep | 4 | 2002 | 169 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2014 | 279 | 0.100 |
Why?
|
| Plaque, Amyloid | 1 | 2012 | 38 | 0.100 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 99 | 0.100 |
Why?
|
| DNA Primers | 2 | 2008 | 289 | 0.100 |
Why?
|
| Receptor, Notch4 | 2 | 2008 | 4 | 0.100 |
Why?
|
| Genetic Vectors | 4 | 2019 | 808 | 0.100 |
Why?
|
| Virus Shedding | 1 | 2012 | 19 | 0.100 |
Why?
|
| Lovastatin | 1 | 2011 | 2 | 0.100 |
Why?
|
| Proteins | 2 | 2014 | 730 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-rel | 2 | 2015 | 15 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2011 | 34 | 0.090 |
Why?
|
| Semen | 1 | 2012 | 42 | 0.090 |
Why?
|
| HIV | 1 | 2012 | 68 | 0.090 |
Why?
|
| Receptors, Estrogen | 2 | 2010 | 124 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 66 | 0.090 |
Why?
|
| Interleukin-2 | 3 | 2003 | 164 | 0.090 |
Why?
|
| Transplantation, Homologous | 2 | 2023 | 244 | 0.090 |
Why?
|
| Cytomegalovirus | 1 | 2012 | 90 | 0.090 |
Why?
|
| DNA | 3 | 2002 | 805 | 0.090 |
Why?
|
| Cytoplasm | 1 | 2012 | 270 | 0.090 |
Why?
|
| HeLa Cells | 3 | 2019 | 526 | 0.090 |
Why?
|
| Histocompatibility Antigens Class II | 5 | 1983 | 182 | 0.090 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2010 | 5 | 0.090 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 228 | 0.090 |
Why?
|
| Male | 8 | 2024 | 27747 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 858 | 0.090 |
Why?
|
| Shock, Septic | 1 | 2011 | 86 | 0.090 |
Why?
|
| Adult | 4 | 2024 | 15683 | 0.090 |
Why?
|
| Middle Aged | 4 | 2024 | 16314 | 0.090 |
Why?
|
| Drug Synergism | 2 | 2011 | 132 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 527 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 836 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 152 | 0.080 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2010 | 29 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 2052 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2009 | 45 | 0.080 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 1994 | 397 | 0.080 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 2 | 2002 | 17 | 0.080 |
Why?
|
| Haplotypes | 1 | 1989 | 115 | 0.080 |
Why?
|
| DNA, Complementary | 4 | 2001 | 164 | 0.080 |
Why?
|
| Models, Biological | 4 | 2003 | 1143 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 70 | 0.080 |
Why?
|
| Perforin | 1 | 2009 | 31 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2008 | 135 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 450 | 0.080 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2009 | 108 | 0.080 |
Why?
|
| Cyclin D3 | 1 | 2008 | 4 | 0.080 |
Why?
|
| Receptor, Notch3 | 1 | 2008 | 8 | 0.080 |
Why?
|
| Retinoblastoma Protein | 1 | 2008 | 36 | 0.080 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2008 | 46 | 0.080 |
Why?
|
| RNA Interference | 3 | 2020 | 590 | 0.080 |
Why?
|
| Mice, Inbred CBA | 1 | 1988 | 83 | 0.080 |
Why?
|
| Immunoglobulin alpha-Chains | 1 | 1988 | 3 | 0.080 |
Why?
|
| G1 Phase | 1 | 2008 | 55 | 0.080 |
Why?
|
| Azepines | 1 | 2008 | 19 | 0.080 |
Why?
|
| S Phase | 1 | 2008 | 74 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 365 | 0.080 |
Why?
|
| Smad Proteins | 1 | 2008 | 21 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2009 | 170 | 0.070 |
Why?
|
| Alanine | 1 | 2008 | 49 | 0.070 |
Why?
|
| Immunoglobulin G | 4 | 2010 | 446 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2020 | 516 | 0.070 |
Why?
|
| Transcription Factor HES-1 | 1 | 2008 | 6 | 0.070 |
Why?
|
| Heterografts | 2 | 2019 | 61 | 0.070 |
Why?
|
| Neoplasm Proteins | 3 | 2008 | 278 | 0.070 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2007 | 22 | 0.070 |
Why?
|
| Inflammation | 1 | 2014 | 1099 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2008 | 111 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2008 | 194 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 588 | 0.070 |
Why?
|
| Kidney | 1 | 1989 | 414 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 124 | 0.070 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2008 | 205 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2007 | 66 | 0.070 |
Why?
|
| Borrelia burgdorferi | 1 | 2007 | 68 | 0.070 |
Why?
|
| Peyer's Patches | 3 | 2002 | 36 | 0.070 |
Why?
|
| Genes | 4 | 2002 | 90 | 0.070 |
Why?
|
| Histocompatibility Antigens | 2 | 1983 | 107 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 254 | 0.060 |
Why?
|
| Hydrogen Peroxide | 2 | 2003 | 76 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2005 | 26 | 0.060 |
Why?
|
| Human papillomavirus 6 | 1 | 2005 | 4 | 0.060 |
Why?
|
| Cell Transformation, Viral | 1 | 2005 | 15 | 0.060 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2005 | 23 | 0.060 |
Why?
|
| Binding Sites | 3 | 2015 | 881 | 0.060 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 36 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 194 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2015 | 65 | 0.060 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2005 | 19 | 0.060 |
Why?
|
| Substrate Specificity | 2 | 2019 | 333 | 0.060 |
Why?
|
| Oncogenes | 1 | 2005 | 66 | 0.060 |
Why?
|
| Receptors, Antigen | 1 | 2005 | 7 | 0.060 |
Why?
|
| Immunoglobulin A | 1 | 1986 | 94 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2005 | 188 | 0.060 |
Why?
|
| Lymphopoiesis | 1 | 2005 | 27 | 0.060 |
Why?
|
| Swine, Miniature | 2 | 1983 | 8 | 0.060 |
Why?
|
| HIV Infections | 1 | 2012 | 913 | 0.060 |
Why?
|
| Cytosol | 1 | 2005 | 171 | 0.060 |
Why?
|
| Ileum | 2 | 2002 | 20 | 0.060 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 47 | 0.060 |
Why?
|
| HLA-DR3 Antigen | 2 | 2016 | 6 | 0.060 |
Why?
|
| Hematopoiesis | 1 | 2005 | 120 | 0.060 |
Why?
|
| Wnt Proteins | 1 | 2005 | 91 | 0.060 |
Why?
|
| Genes, p53 | 2 | 1996 | 52 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2005 | 83 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 718 | 0.060 |
Why?
|
| Protein Conformation | 2 | 2006 | 763 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 2002 | 381 | 0.060 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Light Chain | 3 | 2001 | 5 | 0.060 |
Why?
|
| Fetus | 2 | 2001 | 93 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2003 | 215 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 2 | 1995 | 138 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 354 | 0.050 |
Why?
|
| Mutation | 4 | 2007 | 2456 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1996 | 111 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 46 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2016 | 258 | 0.050 |
Why?
|
| Hematopoietic System | 1 | 2002 | 10 | 0.050 |
Why?
|
| Particle Size | 2 | 2021 | 395 | 0.050 |
Why?
|
| Chromosomes, Artificial, Human | 1 | 2002 | 1 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2020 | 513 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2023 | 192 | 0.050 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2002 | 38 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 440 | 0.050 |
Why?
|
| Carbonic Anhydrases | 1 | 2002 | 8 | 0.050 |
Why?
|
| ras Proteins | 1 | 2002 | 77 | 0.050 |
Why?
|
| Jurkat Cells | 3 | 2012 | 104 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2002 | 29 | 0.050 |
Why?
|
| Adenosine | 1 | 2022 | 70 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2022 | 36 | 0.050 |
Why?
|
| Organ Specificity | 2 | 2019 | 183 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 202 | 0.050 |
Why?
|
| Calcimycin | 2 | 1999 | 19 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2002 | 97 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1999 | 65 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2002 | 193 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2018 | 205 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2015 | 95 | 0.040 |
Why?
|
| Genes, MHC Class II | 2 | 1995 | 37 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 689 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 2010 | 179 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 85 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 56 | 0.040 |
Why?
|
| Biomarkers | 2 | 2015 | 1307 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 103 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2020 | 184 | 0.040 |
Why?
|
| Gene Order | 1 | 2019 | 29 | 0.040 |
Why?
|
| Alleles | 4 | 1989 | 411 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2019 | 62 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5281 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2019 | 141 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 1999 | 39 | 0.040 |
Why?
|
| Forecasting | 1 | 1999 | 221 | 0.040 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 1999 | 38 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 1999 | 44 | 0.040 |
Why?
|
| Macromolecular Substances | 2 | 2014 | 160 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 2 | 2002 | 178 | 0.040 |
Why?
|
| Retroviridae | 1 | 1999 | 69 | 0.040 |
Why?
|
| Calcium Channels | 1 | 1999 | 101 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 1 | 2018 | 51 | 0.040 |
Why?
|
| Research | 1 | 2000 | 188 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2018 | 95 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2010 | 179 | 0.040 |
Why?
|
| Thymoma | 1 | 1978 | 11 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 171 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2018 | 123 | 0.040 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2017 | 4 | 0.040 |
Why?
|
| Antigens, Viral | 2 | 1995 | 130 | 0.040 |
Why?
|
| Cell Membrane | 3 | 2014 | 486 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 234 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2018 | 149 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 40 | 0.030 |
Why?
|
| Phenotype | 2 | 2016 | 1137 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 140 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1997 | 13 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 1997 | 27 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 1997 | 41 | 0.030 |
Why?
|
| DNA Ligases | 1 | 1996 | 4 | 0.030 |
Why?
|
| Leupeptins | 1 | 1996 | 15 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 847 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2017 | 87 | 0.030 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1996 | 21 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 1996 | 54 | 0.030 |
Why?
|
| Mammary Glands, Animal | 1 | 1997 | 78 | 0.030 |
Why?
|
| Genomic Library | 1 | 1996 | 10 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1996 | 288 | 0.030 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2015 | 6 | 0.030 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 248 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2015 | 39 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2015 | 73 | 0.030 |
Why?
|
| Species Specificity | 3 | 1997 | 329 | 0.030 |
Why?
|
| Electron Transport | 2 | 2014 | 35 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 661 | 0.030 |
Why?
|
| Biocatalysis | 1 | 2015 | 45 | 0.030 |
Why?
|
| Fluconazole | 1 | 1995 | 13 | 0.030 |
Why?
|
| DNA, Antisense | 1 | 1995 | 17 | 0.030 |
Why?
|
| Child, Preschool | 2 | 1998 | 1793 | 0.030 |
Why?
|
| Chick Embryo | 2 | 1994 | 42 | 0.030 |
Why?
|
| Calcium | 1 | 1999 | 555 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 333 | 0.030 |
Why?
|
| Antigens, Surface | 2 | 1995 | 192 | 0.030 |
Why?
|
| Adiposity | 1 | 2015 | 74 | 0.030 |
Why?
|
| Rats | 2 | 2001 | 1910 | 0.030 |
Why?
|
| Candida | 1 | 1995 | 35 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2015 | 65 | 0.030 |
Why?
|
| Povidone | 1 | 1995 | 8 | 0.030 |
Why?
|
| Candidiasis | 1 | 1995 | 45 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 1995 | 14 | 0.030 |
Why?
|
| Solubility | 2 | 2014 | 177 | 0.030 |
Why?
|
| Replication Origin | 1 | 1995 | 35 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 359 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 303 | 0.030 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 1995 | 26 | 0.030 |
Why?
|
| Genes, jun | 1 | 2014 | 2 | 0.030 |
Why?
|
| Mitochondrial Membranes | 1 | 2014 | 4 | 0.030 |
Why?
|
| Tumor Necrosis Factors | 1 | 2014 | 8 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2014 | 5 | 0.030 |
Why?
|
| ADAM17 Protein | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cell Separation | 1 | 1995 | 145 | 0.030 |
Why?
|
| Ganglia, Sympathetic | 1 | 1994 | 5 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 191 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 153 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 1995 | 60 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2015 | 293 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2015 | 196 | 0.030 |
Why?
|
| Genes, Helminth | 1 | 1994 | 53 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2014 | 39 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Methylation | 1 | 2014 | 124 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 203 | 0.030 |
Why?
|
| Body Weight | 1 | 2015 | 368 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 540 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1994 | 99 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2003 | 1466 | 0.030 |
Why?
|
| Methacrylates | 1 | 2014 | 37 | 0.030 |
Why?
|
| Caspase 1 | 1 | 1994 | 107 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1994 | 152 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 356 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 1994 | 146 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 191 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1995 | 137 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1994 | 96 | 0.030 |
Why?
|
| Trans-Activators | 1 | 1995 | 300 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2015 | 359 | 0.030 |
Why?
|
| Moths | 1 | 1993 | 24 | 0.030 |
Why?
|
| Metamorphosis, Biological | 1 | 1993 | 30 | 0.030 |
Why?
|
| DNA Repair | 1 | 1995 | 242 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2014 | 260 | 0.030 |
Why?
|
| Dependovirus | 1 | 2019 | 652 | 0.030 |
Why?
|
| Glucose | 1 | 2015 | 445 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 490 | 0.030 |
Why?
|
| Respirovirus Infections | 1 | 1992 | 6 | 0.020 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 1992 | 17 | 0.020 |
Why?
|
| Drug Design | 1 | 2013 | 136 | 0.020 |
Why?
|
| Fluorescence | 1 | 1992 | 83 | 0.020 |
Why?
|
| Proteolysis | 1 | 2013 | 136 | 0.020 |
Why?
|
| Proteomics | 1 | 2014 | 263 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2012 | 105 | 0.020 |
Why?
|
| Superantigens | 1 | 2011 | 10 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1119 | 0.020 |
Why?
|
| Insulin | 1 | 2015 | 673 | 0.020 |
Why?
|
| Immunity, Mucosal | 1 | 2012 | 49 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 1992 | 102 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 93 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1128 | 0.020 |
Why?
|
| Chromosomes | 1 | 1993 | 135 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2012 | 88 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 795 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 220 | 0.020 |
Why?
|
| DNA Damage | 1 | 1993 | 279 | 0.020 |
Why?
|
| Permeability | 1 | 2010 | 49 | 0.020 |
Why?
|
| Polymers | 1 | 2014 | 316 | 0.020 |
Why?
|
| Antitoxins | 1 | 2010 | 2 | 0.020 |
Why?
|
| Blood | 1 | 2010 | 29 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 81 | 0.020 |
Why?
|
| Keratins | 1 | 2010 | 30 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 24 | 0.020 |
Why?
|
| Virginia | 1 | 1989 | 23 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2010 | 118 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2009 | 16 | 0.020 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2009 | 9 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 161 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2009 | 35 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 108 | 0.020 |
Why?
|
| Nephrectomy | 1 | 1989 | 66 | 0.020 |
Why?
|
| Survival Rate | 1 | 2011 | 801 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2009 | 128 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 178 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1988 | 52 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 1998 | 5119 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 1988 | 35 | 0.020 |
Why?
|
| Codon | 1 | 1988 | 48 | 0.020 |
Why?
|
| Swine | 3 | 1983 | 354 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2008 | 68 | 0.020 |
Why?
|
| Cisplatin | 1 | 2008 | 119 | 0.020 |
Why?
|
| Radiography | 1 | 1989 | 516 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2002 | 217 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2007 | 23 | 0.020 |
Why?
|
| Biological Products | 1 | 2008 | 90 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1986 | 284 | 0.020 |
Why?
|
| Cross Reactions | 2 | 1983 | 127 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1983 | 178 | 0.020 |
Why?
|
| Aging | 1 | 2012 | 710 | 0.020 |
Why?
|
| Phytohemagglutinins | 2 | 2003 | 15 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 2338 | 0.020 |
Why?
|
| Concanavalin A | 2 | 1983 | 40 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 297 | 0.020 |
Why?
|
| Immunoglobulins | 2 | 1983 | 76 | 0.020 |
Why?
|
| Sarcoma | 2 | 1983 | 36 | 0.020 |
Why?
|
| Lymphoid Tissue | 2 | 1997 | 55 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2007 | 153 | 0.020 |
Why?
|
| Cell Count | 2 | 1983 | 127 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1985 | 32 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1985 | 52 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 472 | 0.010 |
Why?
|
| Glycoproteins | 2 | 1983 | 186 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1983 | 12 | 0.010 |
Why?
|
| Haploidy | 1 | 1983 | 10 | 0.010 |
Why?
|
| Brain | 1 | 2012 | 1488 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2003 | 18 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 1983 | 12 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1983 | 16 | 0.010 |
Why?
|
| Lipid A | 1 | 2003 | 66 | 0.010 |
Why?
|
| Chromatin | 1 | 2008 | 599 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2003 | 65 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2003 | 145 | 0.010 |
Why?
|
| Hydrostatic Pressure | 1 | 2002 | 4 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 12 | 0.010 |
Why?
|
| Dehydroascorbic Acid | 1 | 2002 | 2 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 25 | 0.010 |
Why?
|
| Melanoma | 2 | 2003 | 318 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 157 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2002 | 25 | 0.010 |
Why?
|
| Catalase | 1 | 2002 | 23 | 0.010 |
Why?
|
| Hyperoxia | 1 | 2002 | 16 | 0.010 |
Why?
|
| Aged | 1 | 1998 | 13406 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 76 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1983 | 185 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 103 | 0.010 |
Why?
|
| Membranes | 1 | 2002 | 19 | 0.010 |
Why?
|
| Mammals | 1 | 2003 | 209 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 127 | 0.010 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2001 | 7 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 366 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 177 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2002 | 280 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1981 | 31 | 0.010 |
Why?
|
| Immunoglobulin J-Chains | 1 | 2001 | 1 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 247 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2001 | 46 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2001 | 25 | 0.010 |
Why?
|
| Epitopes | 2 | 1983 | 286 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2002 | 253 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 327 | 0.010 |
Why?
|
| Rosette Formation | 1 | 1980 | 12 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2002 | 303 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 1999 | 15 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 33 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2000 | 66 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 1999 | 44 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1998 | 230 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1999 | 177 | 0.010 |
Why?
|
| Point Mutation | 1 | 1998 | 160 | 0.010 |
Why?
|
| Plasmacytoma | 1 | 1978 | 9 | 0.010 |
Why?
|
| Retinal Pigments | 1 | 1977 | 5 | 0.010 |
Why?
|
| Clone Cells | 1 | 1978 | 106 | 0.010 |
Why?
|
| Rhodopsin | 1 | 1977 | 13 | 0.010 |
Why?
|
| Photoreceptor Cells | 1 | 1977 | 20 | 0.010 |
Why?
|
| Autophagy | 1 | 2000 | 213 | 0.010 |
Why?
|
| Pseudogenes | 1 | 1997 | 12 | 0.010 |
Why?
|
| Antibody-Producing Cells | 1 | 1977 | 14 | 0.010 |
Why?
|
| Germinal Center | 1 | 1997 | 38 | 0.010 |
Why?
|
| Mercaptoethanol | 1 | 1996 | 4 | 0.010 |
Why?
|
| Anaerobiosis | 1 | 1996 | 15 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1996 | 68 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 3615 | 0.010 |
Why?
|
| Arboviruses | 1 | 1975 | 1 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1996 | 119 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1995 | 21 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 1995 | 29 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1995 | 47 | 0.010 |
Why?
|
| Endotoxins | 1 | 1976 | 78 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1976 | 171 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 1977 | 283 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1994 | 53 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1995 | 554 | 0.010 |
Why?
|
| Virus Replication | 1 | 1975 | 305 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1993 | 31 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1995 | 715 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1994 | 148 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1994 | 146 | 0.010 |
Why?
|
| Adolescent | 2 | 1995 | 5838 | 0.010 |
Why?
|
| HLA-DR Antigens | 2 | 1983 | 27 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1995 | 349 | 0.010 |
Why?
|
| Ribavirin | 1 | 1992 | 24 | 0.010 |
Why?
|
| Personnel, Hospital | 1 | 1992 | 41 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1983 | 184 | 0.010 |
Why?
|
| Family Health | 1 | 1992 | 67 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 1992 | 84 | 0.010 |
Why?
|
| Cross Infection | 1 | 1992 | 149 | 0.010 |
Why?
|
| Mice, Inbred C3H | 2 | 1983 | 173 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1992 | 263 | 0.010 |
Why?
|
| Age Factors | 1 | 1994 | 1504 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 1980 | 33 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1995 | 3067 | 0.000 |
Why?
|
| Infant | 1 | 1992 | 1492 | 0.000 |
Why?
|
| Isoantigens | 2 | 1977 | 71 | 0.000 |
Why?
|
| Aneuploidy | 1 | 1985 | 40 | 0.000 |
Why?
|
| RNA, Double-Stranded | 1 | 1985 | 106 | 0.000 |
Why?
|
| Mice, Inbred A | 1 | 1983 | 20 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1983 | 84 | 0.000 |
Why?
|
| Child | 1 | 1992 | 4189 | 0.000 |
Why?
|
| Rabbits | 1 | 1983 | 322 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1983 | 114 | 0.000 |
Why?
|
| Papain | 1 | 1981 | 3 | 0.000 |
Why?
|
| Iodoacetamide | 1 | 1981 | 3 | 0.000 |
Why?
|
| Isoelectric Focusing | 1 | 1981 | 9 | 0.000 |
Why?
|
| Goats | 1 | 1981 | 9 | 0.000 |
Why?
|
| Ultracentrifugation | 1 | 1981 | 28 | 0.000 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1981 | 25 | 0.000 |
Why?
|
| Prognosis | 1 | 1985 | 1597 | 0.000 |
Why?
|
| Antilymphocyte Serum | 1 | 1980 | 20 | 0.000 |
Why?
|
| Chromosome Banding | 1 | 1980 | 10 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1980 | 17 | 0.000 |
Why?
|
| Monocytes | 1 | 1980 | 345 | 0.000 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1977 | 25 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1978 | 100 | 0.000 |
Why?
|
| Peptides | 1 | 1981 | 549 | 0.000 |
Why?
|
| Immunoglobulin Allotypes | 1 | 1977 | 2 | 0.000 |
Why?
|
| Immunoglobulin D | 1 | 1977 | 8 | 0.000 |
Why?
|
| Dinitrobenzenes | 1 | 1977 | 6 | 0.000 |
Why?
|
| Haptens | 1 | 1977 | 13 | 0.000 |
Why?
|
| Binding Sites, Antibody | 1 | 1977 | 23 | 0.000 |
Why?
|
| Lymphokines | 1 | 1977 | 65 | 0.000 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1977 | 58 | 0.000 |
Why?
|
| Immunoglobulin M | 1 | 1977 | 114 | 0.000 |
Why?
|
| Poly I | 1 | 1976 | 1 | 0.000 |
Why?
|
| Sindbis Virus | 1 | 1975 | 1 | 0.000 |
Why?
|
| Encephalitis Virus, Japanese | 1 | 1975 | 2 | 0.000 |
Why?
|
| Cytochalasin B | 1 | 1975 | 23 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1977 | 697 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1976 | 695 | 0.000 |
Why?
|